Daiichi Sankyo Company, Limited (DSNKY)
DSNKY Stock Price Chart
Explore Daiichi Sankyo Company, Limited interactive price chart. Choose custom timeframes to analyze DSNKY price movements and trends.
DSNKY Company Profile
Discover essential business fundamentals and corporate details for Daiichi Sankyo Company, Limited (DSNKY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
12 Dec 2008
Employees
18.73K
Website
https://www.daiichisankyo.comCEO
Hiroyuki Okuzawa
Description
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
DSNKY Financial Timeline
Browse a chronological timeline of Daiichi Sankyo Company, Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 23 Apr 2026
Upcoming earnings on 29 Jan 2026
Upcoming earnings on 30 Oct 2025
Revenue estimate is $491.47B.
Earnings released on 29 Jul 2025
Earnings released on 25 Apr 2025
EPS came in at $0.32 , while revenue for the quarter reached $3.57B , missing expectations by -99.22%.
Earnings released on 29 Jan 2025
EPS came in at $0.21 , while revenue for the quarter reached $3.08B , missing expectations by -99.36%.
Earnings released on 31 Oct 2024
EPS came in at $0.22 , while revenue for the quarter reached $3.00B .
Dividend declared on 30 Sept 2024
A dividend of $0.14 per share was announced, adjusted to $0.14. The dividend was paid on 17 Dec 2024.
Earnings released on 31 Jul 2024
EPS came in at $0.28 , while revenue for the quarter reached $2.72B .
Earnings released on 25 Apr 2024
EPS came in at $0.13 , while revenue for the quarter reached $2.82B .
Dividend declared on 27 Mar 2024
A dividend of $0.19 per share was announced, adjusted to $0.19. The dividend was paid on 25 Jun 2024.
Earnings released on 21 Mar 2024
EPS came in at $0.25 , while revenue for the quarter reached $3.19B .
Earnings released on 31 Jan 2024
EPS came in at $0.14 , while revenue for the quarter reached $2.51B .
Dividend declared on 28 Sept 2023
A dividend of $0.14 per share was announced, adjusted to $0.14. The dividend was paid on 15 Dec 2023.
Earnings released on 30 Jun 2023
EPS came in at $0.21 , while revenue for the quarter reached $2.43B .
Earnings released on 31 Mar 2023
EPS came in at $0.09 , while revenue for the quarter reached $2.49B .
Dividend declared on 30 Mar 2023
A dividend of $0.11 per share was announced, adjusted to $0.11. The dividend was paid on 27 Jun 2023.
Earnings released on 31 Dec 2022
EPS came in at $0.11 , while revenue for the quarter reached $2.62B .
Earnings released on 30 Sept 2022
EPS came in at $0.14 , while revenue for the quarter reached $2.26B .
Dividend declared on 29 Sept 2022
A dividend of $0.11 per share was announced, adjusted to $0.11. The dividend was paid on 8 Dec 2022.
Earnings released on 30 Jun 2022
EPS came in at $0.07 , while revenue for the quarter reached $2.06B .
Earnings released on 31 Mar 2022
EPS came in at -$0.12 , while revenue for the quarter reached $1.91B .
Dividend declared on 30 Mar 2022
A dividend of $0.10 per share was announced, adjusted to $0.10. The dividend was paid on 5 Jul 2022.
Earnings released on 31 Dec 2021
EPS came in at $0.14 , while revenue for the quarter reached $2.44B .
Earnings released on 30 Sept 2021
EPS came in at $0.13 , while revenue for the quarter reached $2.39B .
Dividend declared on 28 Sept 2021
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 9 Dec 2021.
Earnings released on 30 Jun 2021
EPS came in at $0.17 , while revenue for the quarter reached $2.38B .
Earnings released on 31 Mar 2021
EPS came in at $0.00 , while revenue for the quarter reached $2.02B .
Dividend declared on 29 Mar 2021
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 29 Jun 2021.
Earnings released on 31 Dec 2020
EPS came in at $0.12 , while revenue for the quarter reached $2.50B .
Stock split effective on 9 Oct 2020
Shares were split 3 : 1 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Sept 2020
EPS came in at $0.10 , while revenue for the quarter reached $2.30B .
Dividend declared on 28 Sept 2020
A dividend of $0.39 per share was announced, adjusted to $0.13. The dividend was paid on 8 Dec 2020.
DSNKY Stock Performance
Access detailed DSNKY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.